TNF and rheumatoid arthritis: Last but not least, tofacitinib in bDMARD-IR was also assessed in ORAL-step, a 6-month, double-blind, parallel-group phase 3 study.28 399 patients with moderate-to-severe RA and inadequate anti-TNF were randomly assigned to tofacitinib bd 5 mg (n=133); tofacitinib bd 10 mg (n=134); or placebo (n=132), all with background methotrexate.